Inovio Pharmaceuticals, Inc. (INO) Cash Flow Statement

The operating cash flow to net income ratio is distorted by the fact that both figures are negative in most quarters, so the ratio carries little analytical meaning here. The more informative observation is that operating cash outflows have trended lower from the 2024 peak, which may suggest some cost discipline, though the absolute burn remains large relative to any reported revenue. Investors should monitor whether this trend continues, as the reported figures alone do not establish sustainability.

Because reported revenue is sporadic and near zero, FCF margin is not a reliable benchmark for judging operating efficiency in this name. Capital expenditures are immaterial, so free cash flow is effectively equal to operating cash flow, meaning the burn is driven almost entirely by operating outlays. This suggests the business depends on its existing liquidity or external financing, a conclusion that warrants further investigation given the data provided.

Low capex is consistent with a research-stage biotechnology model that outsources or defers large physical investment, and D&A of roughly $750K to $830K per quarter is similarly small. The near-zero capex means the cash profile is shaped by operating expense rather than asset build-out. This may indicate limited near-term manufacturing commitments, though the data does not confirm the company's plans.

The cumulative gap between net income and operating cash flow is not the central issue here, since both are consistently negative and move together over the period. Instead, the absence of any capital returns combined with sustained operating burn suggests the company's balance sheet is being drawn down or refilled through external sources. Investors should monitor future liquidity disclosures, as the cash flow data alone cannot establish how this gap is being financed.